Semaglutide and the Gila Monster: Where Did This Connection Come From?

Did semaglutide actually come from gila monster venom?

No. The gila monster story begins in the early 1990s, when researcher John Eng identified a peptide called exendin-4 in the salivary secretions of Heloderma suspectum (the gila monster) and noticed it closely resembled a human hormone called GLP-1. That discovery led to exenatide (brand name Byetta), approved for type 2 diabetes, which is a direct synthetic copy of exendin-4. Exenatide is the medicine that earned the gila monster its place in pharmacology history.

Semaglutide took a different path. Scientists at Novo Nordisk started with the human GLP-1 molecule itself and modified it chemically: a fatty acid chain was added to help it bind to albumin in the blood, extending its half-life to roughly seven days so it only needs to be taken once a week. The result is a medicine that works on the same receptor as exenatide but shares no ingredient with reptile biology. The gila monster venom and semaglutide story is a popular shorthand, understandable, but not quite accurate.

Both drugs are GLP-1 receptor agonists, which is why they are grouped together and why the origin story travels between them. But calling semaglutide a gila monster drug is a bit like calling all penicillins the same thing because they share a mechanism. The detail matters.

What does GLP-1 actually do, and why does that reduce body weight?

GLP-1 is a hormone released by L-cells in your small intestine within minutes of eating. It signals the pancreas to release insulin, tells the stomach to slow how quickly food passes through, and crosses into the brain to reduce appetite. Under normal conditions GLP-1 is broken down within a couple of minutes. Semaglutide holds that signal open for a full week.

The practical effects reported by patients are: meals feel satisfying much sooner, the background noise of hunger is quieter between meals, and highly palatable foods become less compelling. In the STEP 1 clinical trial (68 weeks, semaglutide 2.4 mg against placebo) participants lost an average of around 15% of their body weight, as published in the New England Journal of Medicine. That kind of result requires the medicine to be used alongside a reduced-calorie diet and increased physical activity; it is not a standalone intervention.

A question our prescribers hear most weeks is whether the appetite reduction wears off after a few months. The trial data suggest the effect is sustained for as long as treatment continues; weight tends to return when semaglutide is stopped, which is why ongoing clinical review matters rather than treating it as a short course.

How does the gila monster history fit into the broader development of GLP-1 medicines?

Exendin-4's discovery proved that a GLP-1 receptor could be activated by a non-human peptide, which opened the field. Without that reptile-derived proof of concept, the commercial development of GLP-1 drugs might have taken much longer. In that sense the gila monster is genuinely part of the story of how medicines like Wegovy came to exist, just not an ingredient in them.

Since exenatide, the GLP-1 class has expanded significantly. Semaglutide was developed as a longer-acting, more potent GLP-1 agonist. Tirzepatide (Mounjaro) then added a second receptor pathway (GIP) alongside GLP-1, making it a dual agonist. You can read more about how Wegovy works and what it is licensed for if you're weighing it against other options, or explore the broader weight-loss treatment landscape to see where each medicine sits.

What links all these drugs is the original observation that slowing GLP-1 breakdown changes how the body regulates hunger and blood sugar. The gila monster's saliva provided the first evidence that a molecule could do that without being broken down instantly, a practical insight that shaped a generation of medicines.

What does this mean for someone considering semaglutide for weight management?

The origin story is interesting, but the questions that affect you are more practical. Wegovy is licensed in the UK by the MHRA for adults with a BMI of 30 or above, or 27 or above alongside a condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. NICE's appraisal of semaglutide (TA875) sets out the NHS criteria, which are narrower and involve specialist services; private routes through a regulated online pharmacy offer a different path for people who meet the licensed criteria but are not eligible for NHS treatment or do not want to wait.

The side-effect profile is dominated by gastrointestinal symptoms (nausea, loose stools, constipation and indigestion) most noticeable in the first few weeks or after a dose step up, and usually settling as the body adjusts. More details on what to expect at the early doses are worth reading before starting, and you can also find guidance on what to expect as you move into the semaglutide 2 stage and on how the semaglutide 3 phase is typically managed.

Semaglutide is not recommended during pregnancy, breastfeeding or when actively trying to conceive, and it is not licensed for use in under-18s. Because it slows gastric emptying, women taking oral contraceptives are advised to discuss their contraception method with their prescriber, and the same applies to oral HRT. The NHS semaglutide page covers these interactions in plain language and is a reliable first reference.

If you'd like to explore whether semaglutide is clinically appropriate for you, the first step is a free consultation reviewed by a GPhC-registered prescriber. You can check your eligibility without any commitment, and a real clinician reads every response before any prescription decision is made.